Cutting-Edge HeartCare and AlloMap Solutions Featured at ISHLT 2019
Jon Kobashigawa, MD, Cedars-Sinai Kiran Khush, MD Stanford University Shelley Hall, MD, Baylor Scott& White Eugene DePasquale, MD, UCLA Sean Pinney, MD, Mount Sinai
- Mary Beth Maydosz, NP, Inova
CareDx’s HeartCare and AlloMap surveillance tests will also be featured in the following oral presentations and posters during ISHLT 2019:
Distinct Patterns of Gene Expression Identified Longitudinally and within AlloMap Score Ranges are Associated with Clinical Outcomes.
Are Gene Expression Profile Testing Scores Associated with New Onset Cardiac Allograft Vasculopathy.
Differential Gene Expression by Race and Impact on Risk after Heart Transplantation.
Does Donor-Derived Cell-Free DNA Detect the Development of De Novo Donor-Specific Antibodies. J. Patel, MD:
Use of dd-cfDNA in Multiorgan Transplantation.
Use of dd-cfDNA in Real World Practice: Single Center Experience.
Combination of Cell-Free DNA with Gene-Expression Profiling in the Diagnosis of Acute Rejection (Abstract #975).
“CareDx is committed to providing best-in-class solutions for transplant patients,” said
For more information, please visit: www.CareDx.com.
Forward Looking Statements
This press release includes forward-looking statements, including statements regarding the Company’s participation at ISHLT. These forward-looking statements are based upon information that is currently available to
Chief Commercial Officer
Integrated Corporate Relations, Inc.
Source: CareDx, Inc.